A double-blind, placebo-controlled, 3-arm, fixed-dose study of 12.5 mg/day and 25mg/day Paroxetine CR in the treatment of Major Depression.
Depressive Disorder, Major
Phase 4
The data from this study is provided in combined datasets containing data from other paroxetine studies. An annotated case report form and a reporting and analysis plan are not available for this study. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
May 2014